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Activation of Akt and the genesis of cancer
The evolutionarily conserved serine/threonine kinase Akt, also
known as protein kinase B (PKB), is one of the most frequently
activated protein kinases in human cancer. Hyperactivation of
Akt is associated with resistance to apoptosis, increased cell
growth, cell proliferation, and cellular energy metabolism.
Mammalian cells express three highly homologous Akt isoforms
(Akt1–3) that are encoded by separate genes and share over
80% amino acid sequence identity. The pathway leading to Akt
activation is highly conserved across species. Upon activation,
growth factor receptors activate the catalytic p110 subunit of
phosphatidylinositol 3-kinase (PI3K) via recruitment of the cor-
responding p85 regulatory subunit or via Ras activation, which
can directly activate p110. p110 then phosphorylates phospho-
inositides (PI) at the D3-position of the inositol ring to generate
PI (3,4,5) P3 (PIP3). The rate-limiting step in Akt-activation is
the binding of PIP3 to the PH domain of Akt and subsequent
translocation of Akt to the plasma membrane. Akt is then phos-
phorylated by PI3K-dependent kinase-1 (PDK1) at a threonine
residue in the catalytic domain (Thr 308), and by another as yet
incompletely defined PI3K-dependent kinase (PDK2) at a ser-
ine residue (Ser 473) in the carboxy-terminal hydrophobic motif
(Figure 1). Phosphorylation at both sites is required for full acti-
vation of Akt (reviewed in Brazil and Hemmings, 2001; Lawlor
and Alessi, 2001). Antagonizing PI3K activity negatively regu-
lates Akt activity. Indeed, Akt activity is negatively regulated by
the tumor suppressor PTEN (phosphatase and tensin homolog
deleted on chromosome ten) (Cantley and Neel, 1999), a phos-
pholipid phosphatase that antagonizes the activity of PI3K by
dephosphorylating PIP3 (see Figure 1).
A number of nonexclusive mechanisms contribute to Akt
hyperactivation in human cancer. Inactivating mutations or dele-
tions of PTEN lead to Akt activation and occur frequently in
human cancers, with a high incidence in prostate and endome-
trial cancers, glioblastoma, and melanoma (Cantley and Neel,
1999). PTEN haplodeficiency has also been associated with the
development of a diverse array of tumors in mice. Although
complete deficiency of PTEN is embryonic lethal, three different
groups have reported a high incidence of tumors of the
prostate, endometrium, thyroid, adrenal medulla, colon, and
hematopoietic cells in Pten heterozygous mice of varying
genetic background (Di Cristofano et al., 1998; Podsypanina et
al., 1999; Suzuki et al., 1998a). Amplification and overexpres-
sion of the gene encoding the p110 catalytic subunit of PI3K is
also observed in a subset of human cancers (Shayesteh et al.,
1999). More recently, mutations in one of the genes encoding
p110 have been observed in a large number of human cancers,
which are likely to activate Akt (Kang et al., 2005). Activating
Ras mutations can also potentially activate Akt and occur in
nearly a third of epithelial tumors (Downward, 2003). Akt gene
amplification has also been observed in a subset of human can-
cers. Lastly, the increased receptor tyrosine kinase activation
observed in many human cancers can activate Akt. Perhaps the
best example involves heterodimeric ErbB-2/ErbB-3 receptor
activation, which frequently occurs in cancer cells and results in
robust PI3K activation that can be attributed, in part, to the exis-
tence of six PI3K docking sites in ErbB-3. Thus, Akt appears to
be hyperactivated in the majority of human cancers, implying
that Akt activation plays a pivotal role in the genesis of cancer.
Akt can potentially phosphorylate over 9000 proteins in
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The downstream effector of PI3K, Akt, is frequently hyperactivated in human cancers. A critical downstream effector of Akt,
which contributes to tumorigenesis, is mTOR. In the PI3K/Akt/mTOR pathway, Akt is flanked by two tumor suppressors: PTEN,
acting as a brake upstream of Akt, and TSC1/TSC2 heterodimer, acting as a brake downstream of Akt and upstream of mTOR.
In the absence of the TSC1/TSC2 brake, mTOR activity is unleashed to inhibit Akt via an inhibitory feedback mechanism.Two
recent studies used mouse genetics to assess the roles of PTEN and TSC2 in cancer, underscoring the importance of Akt-
mTOR interplay for cancer progression and therapy.
Figure 1. In the PI3K/Akt/mTOR pathway, Akt is flanked by two tumor sup-
pressors: PTEN, which antagonizes PI3K and therefore inhibits Akt, and
TSC1/TSC2 heterodimer, which inhibits mTOR by inhibiting the activity of
Rheb
Akt activates mTOR via direct phosphorylation of TSC2 and by the inhibition
of AMPK, thereby activating Rheb and mTOR-Raptor activity. Upon activa-
tion, mTOR-Raptor activates S6K and inhibits 4E-BP to accelerate mRNA
translation, and also initiates feedback inhibition of Akt, which is at least in
part mediated by S6K (for details see text).
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mammalian cells (Lawlor and Alessi, 2001). However, it remains
to be determined which downstream effectors of Akt are most
critical for the genesis of cancer. Several lines of evidence point
to the two most evolutionarily conserved downstream effectors,
the forkhead family of transcription factors, FOXO, and the
mammalian target of rapamycin, mTOR (Figure 1). FOXO tran-
scription factors, which inhibit mammalian cell proliferation, are
directly phosphorylated and inactivated by Akt (Tran et al.,
2003), whereas mTOR, which is associated with increased cell
proliferation, is indirectly activated by Akt.
The interplay between Akt and mTOR
One mechanism whereby Akt can activate mTOR is through
direct phosphorylation of tuberous sclerosis complex 2 (TSC2),
which otherwise inhibits mTOR activity (Figure 1; Hay and
Sonenberg, 2004). Tuberous sclerosis complex 1 (TSC1) and
TSC2 form a heterodimer with GTPase activity that inhibits the
activity of Rheb, a small GTPase required for mTOR activation
(Figure 1; Hay and Sonenberg, 2004). This mechanism of
mTOR activation by Akt is conserved in Drosophila. In addition,
TSC2 is directly phosphorylated and activated by AMPK (Inoki
et al., 2003), and Akt inhibits AMPK activity, via its role in ener-
gy metabolism, to fully inhibit TSC2 and activate mTOR (Hahn-
Windgassen et al., 2005). Thus, activation of Akt could also
inhibit the tumor suppressor activity of AMPK kinase, LKB1
(Figure 1). Germline mutations in the genes encoding TSC1 and
TSC2 are associated with the dominant genetic disorder, tuber-
ous sclerosis (TSC), which is characterized by the development
of benign tumors (hamartomas), and thus, TSC1 and TSC2 are
considered tumor suppressors (Kwiatkowski, 2003). Therefore,
in the PI3K/Akt/mTOR pathway, Akt is flanked by two tumor sup-
pressors, which attenuate the pathway: PTEN, which acts
upstream of Akt, and TSC1/TSC2 heterodimer, which acts
downstream of Akt and upstream of mTOR.
Upon activation, mTOR, which forms a rapamycin-sensitive
complex with Raptor (regulatory-associated protein of mTOR),
increases mRNA translation via activation of S6-kinase and
inhibition of eIF4E binding protein (4E-BP) (Figure 1; Hay and
Sonenberg, 2004). TSC1 or TSC2 deletion constitutively acti-
vates rapamycin-sensitive functions of mTOR independently of
Akt. In contrast, Akt activity is inhibited when mTOR is activated
in TSC1 or TSC2 deficient cells via a negative feedback regula-
tory loop (Figure 1). This feedback inhibitory loop appears to be
conserved in Drosophila (Radimerski et al., 2002) and has been
attributed to the inhibitory effect of S6 Kinase (a downstream
effector of mTOR) on insulin receptor substrate-1 (IRS-1), which
mediates PI3K activation by insulin and IGF-1 (Harrington et al.,
2005). However, this is unlikely to be the only mechanism that
accounts for the negative feedback. A more general mechanism
must exist, because Akt activity is not significantly elevated in
TSC null cells, even when stimulated with serum or PDGF
(platelet-derived growth factor) (Zhang et al., 2003). The rela-
tionship between Akt and mTOR is further complicated by the
existence of mTOR-Rictor (rapamycin-insensitive companion of
mTOR) complex, which possesses the rapamycin-insensitive
mTOR activity. The mTOR-Rictor complex has a conserved
activity that regulates the actin cytoskeleton (Jacinto et al.,
2004; Sarbassov et al., 2004). Recent reports provide evidence
that mTOR-Rictor possesses PDK2 activity, phosphorylating
the serine residue in the C-terminal hydrophobic motif of Akt,
and therefore essential for Akt activity (Sarbassov et al., 2005).
Despite the inhibition of Akt and the activation of FOXO
(Manning et al., 2005), immortalized Tsc2 null cells proliferate
at the same rate or faster than wild-type cells and remain sus-
ceptible to oncogenic transformation to a comparable or greater
extent relative to wild-type cells (Zhang et al., 2003; Ma et al.,
2005a; C.C. Chen, J. Skeen, and N. Hay, unpublished data).This
raises the possibility that mTOR may constitute the most critical
downstream effector of Akt with respect to cell proliferation,
tumorigenesis, and possibly cell survival. In cultured cells,
mTOR inhibition by rapamycin attenuates cell cycle progression
and, in some cases, elicits apoptosis (Hay and Sonenberg,
2004). The rapamycin analog CCI-779 attenuates tumor growth
in Pten+/− mice predisposed to developing a diverse array of
neoplasia (Podsypanina et al., 2001), as well as in cancer cells
lacking functional PTEN (Neshat et al., 2001). Furthermore,
transgenic mice expressing activated Akt in the prostate devel-
op prostate intraepithelial neoplasia (PIN), which is antagonized
by the rapamycin analog RAD001 (Majumder et al., 2004). Also,
overexpression of eIF4E, a downstream effector of mTOR, in
mouse B cell lymphoma accelerates tumorigenesis and mimics
the neoplastic effect of activated Akt in these cells (Wendel et
al., 2004). The critical role that mTOR and mRNA translation
play in tumorigenesis is reinforced by the observation that the
primary effects of oncogenic Ras or Akt on gene expression are
via induction of mRNA translation (Rajasekhar et al., 2003).
The contention that mTOR executes the most critical func-
tions of Akt with regards to cell growth and proliferation is sup-
ported by genetic studies in Drosophila. In Drosophila, both
pten deletion and the loss of either tsc1 or tsc2 result in similar
phenotypes characterized by increased cell size and cell prolif-
eration. Genetic epistasis analyses in Drosophila have shown
that cells doubly deficient for akt (or overexpressing PTEN) and
either tsc1 or tsc2 mimic the phenotype induced by tsc1 or tsc2
inactivation (Potter et al., 2001). Similarly, cells doubly deficient
for pten and tor are indistinguishable from cells lacking tor
alone, which are characterized by reduced cell size and
impaired proliferation (Zhang et al., 2000). Thus, in Drosophila,
TSC1/TSC2 and TOR are epistatic to PTEN and Akt. Based on
these observations, one might expect that mutations in the
genes encoding the tumor suppressors TSC1 and TSC2 should
be frequently observed in a wide spectrum of human cancers,
as is observed for PTEN. However, unlike mutations in the pten
gene, mutations in either tsc1 or tsc2 gene have not yet been
identified in sporadic human cancers (Kwiatkowski, 2003).
Moreover, tuberous sclerosis patients with inherited mutations
in either Tsc1 or Tsc2 develop hamartomas in multiple organs,
but rarely develop malignant cancers (Kwiatkowski, 2003). In
contrast, patients with Cowden disease that harbor Pten gene
mutations develop similar lesions but are predisposed to malig-
nant cancer development (Eng, 2003). Also, when tuberous
sclerosis patients do develop malignant cancer, it is generally
restricted to certain types of tumors such as renal cell carcino-
ma or angiomyolipomas (Kwiatkowski, 2003). Finally, unlike
Pten+/− mice that are predisposed to multiple neoplasia, Tsc2+/−
mice develop mainly kidney tumors and hepatic hemangioma
and, depending on the genetic background, also lung adenoma
and angiosarcoma (Kobayashi et al., 1999; Onda et al., 1999).
Taken together, these observations raise the question of why
TSC1/TSC2 deficiency does not recapitulate the PTEN defi-
ciency in respect to cancer. One possibility is that in vivo, the Akt
inhibition mediated by mTOR activation impedes the tumor pro-
gression promoted by TSC1/TSC2 deficiency. Independent
studies by two different groups have attempted to address this
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issue in vivo in the mouse. Since complete loss of either PTEN
or TSC2 leads to embryonic lethality, both groups employed
Pten+/−, Tsc2+/−, and Pten+/−Tsc2+/−mice to address this question
(Ma et al., 2005b; Manning et al., 2005). Although the source of
Pten+/− mice utilized in both studies was the same, the source of
Tsc2+/− mice was different. The Tsc2+/− mice used by Ma et al.
predominantly develop renal carcinoma and, after a long latent
period, hepatic hemangiomas (Kobayashi et al., 1999), where-
as the Tsc2+/− mice used by Manning et al. develop hepatic
hemangiomas and angiosarcomas in addition to kidney tumors
(Onda et al., 1999).
Based on the epistasis analyses in Drosophila, the deficien-
cy in TSC2 is expected to increase the phenotype of PTEN defi-
ciency, whereas the deficiency in PTEN is not expected to
enhance the phenotype of TSC2 deficiency. Indeed, both
groups found that Pten+/−Tsc2+/− mice display enhanced lymph
node hyperplasia, which is observed in Pten+/− mice and is the
main cause of death of these mice, and therefore there is a sig-
nificant decrease in the life span of Pten+/−Tcs2+/− mice in com-
parison with Pten+/− mice. However, Manning et al. did not find
that TSC2 haplodeficiency enhances the endometrium and
prostate neoplasia, gastrointestinal polyps, or thyroid and
adrenal medulla tumors, which are typically found in Pten+/−
mice. In contrast, Ma et al. found that haplodeficiency of TSC2
accelerates the development of prostatic neoplasia in Pten+/−
mice, since PIN rarely progresses to carcinoma in Pten+/− mice,
whereas progression to carcinoma is frequently observed in
Pten+/−Tsc2+/− mice. In addition, they found that a small percent-
age of the doubly heterozygous mice developed skin cancer,
which was not observed in either of the singly heterozygous
mice. Consistent with what could be extrapolated from the epis-
tasis analyses in Drosophila, Ma et al. found that PTEN haplod-
eficiency did not enhance renal carcinoma development in their
Tsc2+/− mice. Manning et al., however, found that haplodeficien-
cy of PTEN, which only modestly accelerated kidney adeno-
mas, dramatically decreased the latency and increased the
penentrance of liver hemangiomas and angiosarcomas in
Tsc2+/− mice. Both groups attributed the differences in their
results to the different genetic background of the mice used in
these studies. Interestingly, both groups found that the feedback
inhibition of Akt induced by TSC2 deficiency is alleviated by
PTEN haplodeficiency.
Collectively, the results of these studies do not provide a
conclusive explanation for the lack of mutations in Tsc genes in
sporadic cancers, or for the limited spectrum of tumors induced
by TSC2 deficiency. Nevertheless, based on their results,
Manning et al. suggested that the feedback inhibition of Akt
induced by the deletion of TSC2 impedes the progression of
cancer, and that when PTEN level is also reduced, the restored
Akt activity enables faster tumor progression. How does
restoration of Akt activity in Tsc2+/− mice contribute to tumorige-
nesis? As tumorigenesis is a multistep process, which requires
multiple genetic lesions, it is conceivable that Akt activation
accelerates the mutation rate, including the loss of heterozy-
gosity (LOH) of Tsc2 observed in tumors of Tsc2+/− mice.
Notably, activation of Akt or deletion of PTEN could overcome a
G2 cell cycle checkpoint and accelerate mutagenesis (Kandel
et al., 2002; King et al., 2004; Puc et al., 2005). In addition,
accelerated mRNA translation and ribosomal biogenesis
induced by the deficiency of TSC2 consume high levels of cellu-
lar energy. Since Akt is required to maintain cellular energy
metabolism (Hahn-Windgassen et al., 2005), the limited intra-
cellular ATP in Tsc2 null cells could inhibit their survival and pro-
liferation, in particular within a neoplastic lesion, an environ-
ment where nutrients and oxygen have more restricted
availability, unless Akt activity is restored. Other prooncogenic
activities of Akt, particularly its antiapoptotic activities, are also
likely to contribute.
Based upon their results, Ma et al. have provided an alter-
nate explanation for the discrepancy between Pten and Tsc2
mutational frequencies in cancer. These authors found that
while tumors initiated by Tsc2 heterozygosity develop only after
LOH, tumors initiated by Pten heterozygosity can develop in the
absence of LOH. This raised the possibility that PTEN is a hap-
loinsufficient tumor suppressor. Because they also found that
tumors initiated by Pten heterozygosity are accelerated by Tsc2
heterozygosity but do not exhibit LOH at either of the two genes,
they concluded that TSC2 also constitutes a haploinsufficient
tumor suppressor for certain types of cancer.
Are PTEN and TSC2 haploinsufficient tumor suppressors?
According to the classic tumor suppressor two-hit paradigm
defined by Knudson, a germline mutation in a tumor suppressor
gene is followed by the loss of function of the other allele during
tumor development via genetic or epigenetic mechanisms.
However, whether PTEN follows that rule is controversial.
Although biallelic PTEN inactivation is frequently observed in
several types of cancer, the loss of a single allele, with the
preservation of the other allele, is also common. For instance,
LOH at 10q23, the chromosomal localization of PTEN, was
reported to occur in over half of human metastatic prostate can-
cers, but only a third of these cases display biallelic PTEN intra-
genic mutations (Suzuki et al., 1998b). This, however, does not
completely rule out the possibility that the expression of or the
activity of PTEN is either reduced or lost by other documented
epigenetic mechanisms (Kurose et al., 2001). Likewise, despite
the absence of Pten LOH in neoplastic lesions described by Ma
et al., reduced PTEN function by inactivating mutations in the
preserved allele cannot be fully excluded, as this was not
exhaustively examined. Furthermore, these results seemingly
contradict those reported by others demonstrating Pten LOH in
lymphoma, endometrial carcinoma, adrenal tumors, and prosta-
tic neoplasia in Pten+/− mice (Podsypanina et al., 1999;
Podsypanina et al., 2001; Suzuki et al., 1998b). Clearly, the long
latency period required for neoplasia development in Pten+/−
mice, which is markedly shortened in the complete absence of
PTEN (Trotman et al., 2003; Wang et al., 2003), suggests that
the expression and/or activity of the remaining wild-type Pten
allele is somehow affected in this process in Pten+/− mice.
Nevertheless, the absence of LOH at the Pten locus in the
lymph node hyperplasia of Pten+/−mice suggests that haplodefi-
ciency of PTEN is sufficient to confer some cell survival and
possibly proliferative advantage to cause preneoplastic lesions.
The transition to high-grade neoplasia requires additional modi-
fying mutations, including those affecting the wild-type Pten
allele. The list of candidate modifier genes would ostensibly
include regulators of mTOR activity, given the fact that tumori-
genesis is enhanced in Pten+/−Tsc2+/− mice.
Unlike PTEN, both TSC1 and TSC2 follow the classical
tumor suppressor two-hit paradigm in human tumors
(Kwiatkowski, 2003), and LOH is usually observed in tumors
developed in Tsc2+/− mice (Kobayashi et al., 1999; Onda et al.,
1999). However, Ma et al. found that in the prostate neoplasia of
Pten+/−Tsc2+/− mice, there is no Tsc2 LOH, suggesting that when
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PTEN levels are reduced, TSC2 is haploinsufficient to suppress
tumorigenesis. Indeed, they found that, at least ex vivo, mouse
embryonic fibroblasts doubly heterozygous for Pten and Tsc2
exhibit elevated mTOR activity when compared with their singly
heterozygous counterparts.This is consistent with the results of
Manning et al. showing that Pten+/−Tsc2+/− hyperplastic lymph
nodes display elevated mTOR activity in the absence of LOH.
Thus, it is not immediately clear why there is a loss of TSC2 in
kidney tumors and hepatic hemangiomas derived from Pten+/−
Tsc2+/− mice (Kwiatkowski, 2003). Also, if indeed TSC2 is hap-
loinsufficient to suppress tumor development on the
background of other mutations, which enhance PI3K activity, it
is not clear why TSC patients rarely develop malignant cancer,
which is restricted only to certain cell types. Obviously, more
studies are required to resolve this issue.
The implication of Akt-mTOR interactions for cancer therapy
The studies by Ma et al. and Manning et al. underscore the
importance of Akt-mTOR interrelationships for the progression
and therapy of cancer. Akt and mTOR are linked to each other
via positive and negative regulatory circuits, which restrain their
simultaneous hyperactivation (Figure 2). This might have been
evolved as a protection mechanism to inhibit uncontrolled cell
survival and proliferation. As indicated above, the feedback inhi-
bition of Akt induced by hyperactivation of mTOR rapamycin-
sensitive activity was attributed to the inhibitory effect of S6
kinase on IRS-1 downstream of IGF-1 and insulin receptors.
However, the inability of serum or PDGF to overcome this inhibi-
tion, together with the finding by Ma et al. and Manning et al. that
the feedback inhibition also occurs in vivo in mouse tissues that
are exposed to a variety of growth factors, which activate their
cognate receptors and PI3K, points to a more general mecha-
nism. Since haplodeficiency of PTEN is sufficient to alleviate the
feedback inhibition, one possibility is that hyperactivation of the
rapamycin-sensitive activity mTOR could elevate PTEN activity.
Alternatively, the existence of two mTOR complexes may
explain the inhibitory feedback. As indicated above, mTOR
exists in two separate complexes, the mTOR-Raptor, a
rapamycin-sensitive complex, which is activated by Akt, and the
mTOR-Rictor, a rapamycin-insensitive complex, which is acti-
vated by growth factors and possesses PDK2 activity
(Sarbassov et al., 2005). If mTOR-Rictor is indeed the principal
PDK2, following growth factor stimulation, the mTOR-Rictor
complex activates Akt. When activated, AKT inhibits the activity
of TSC1/TSC2 heterodimer to activate Rheb, which in turn pro-
motes the formation of mTOR-Raptor complex to activate the
rapamycin-sensitive activity of mTOR. Assuming that an equilib-
rium exists between these two complexes within the cell, when
the mTOR-Raptor complex is formed, it could antagonize the
formation of mTOR-Rictor complex and therefore reduce Akt
activity (Figure 2). Although speculative, this could provide, in
addition to the documented specific mechanisms (Harrington et
al., 2005; Zhang et al., 2003), a simple general mechanism for
the feedback inhibitory loop. Thus, when mTOR-Raptor is acti-
vated independently of Akt, via the deletion of TSC1/TSC2, it
may inhibit the formation of mTOR-Rictor complex and there-
fore also Akt activation (Figure 2). This is also compatible with
the observation that knockdown of Raptor increases Akt activity
(Sarbassov et al., 2005). Because PDK2 activity is dependent
on PI3K, it is conceivable that reduced activity of PTEN would
enhance mTOR-Rictor activity and therefore alleviate the inhibi-
tion of Akt by the hyperactive mTOR-Raptor complex in TSC-
deficient cells.
The rapamycin derivatives CCI-779, RAD001, and AP23573
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Figure 2. An equilibrium between mTOR-Raptor and mTOR-Rictor complexes could provide an alternative mechanism for the feedback inhibition of Akt by mTOR
A: In wild-type cells, the activation of receptor tyrosine kinase (RTK) leads the activation of PI3K. PI3K then leads to the activation of Akt by inducing its
translocation to the plasma membrane and its phosphorylation by PDK1 and by mTOR-Rictor (PDK2). Upon activation, Akt induces the assembly of the
active mTOR-Raptor complex. The assembly of mTOR-Raptor active complex inhibits the assembly of the mTOR-Rictor active complex, and thereby inhibits
Akt. However, in wild-type cells, this inhibition is transient, because the inhibition of Akt would eventually inhibit mTOR-Raptor. 
B: In TSC-deficient cells, mTOR-Raptor active complex is constitutively active, thereby reducing mTOR-Rictor activity and therefore also Akt activity. 
C: In cells doubly deficient for PTEN and TSC, PI3K is hyperactivated, leading to the hyperactivation of mTOR-Rictor and thereby restoring Akt activity.
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are currently being investigated in clinical trials for cancer thera-
py (Vignot et al., 2005). However, because the primary activity
of rapamycin is to attenuate cell cycle progression and cell
growth, it is not presently clear whether these agents are simply
cytostatic or can also eliminate tumor cells by inducing cell
death. Moreover, because of the negative regulatory loop,
rapamycin can elevate Akt activity (Harrington et al., 2005), this
could pose a significant strategic dilemma when designing can-
cer therapies using these compounds, unless prolonged
rapamycin treatment also impairs mTOR-Rictor complex activity
and consequently Akt activity. In principle, therefore, therapeutic
approaches that simultaneously target both Akt and mTOR-
Raptor may ultimately prove more efficacious.
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